Phase I study of weekly 24-hour infusions of recombinant human interleukin-2

Journal of the National Cancer Institute

Volumn 80, Issue 16, 1988, Pages 1325-1328

  Richards, Jon M ^a   Barker, Ellen ^a   Latta, Jill ^a   Ramming, Kathleen ^a   Vogelzang, Nicholas J ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

CANCER PATIENT; CLINICAL ARTICLE; DRUG THERAPY; EDEMA; EOSINOPHILIA; FEMALE; HUMAN; HYPOTENSION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOPENIA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR;

ADULT; AGED; CARCINOMA, RENAL CELL; DRUG EVALUATION; FEMALE; HUMAN; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGE; RECOMBINANT PROTEINS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023763199     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/80.16.1325     Document Type: Article

References (15)

1. Kvalheim G, Fodstad Ø, Pihl A, et al. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies. Cancer Res 1987;47:846-851
2. Magreth It, Janus C, Edwards Bk, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984;63:1102-1111
3. Melsom H, Funderud S, Lie So, et al. The great majority of childhood lymphoblastic leukaemias are identified by monoclonal antibodies as neoplasias of the B-cell progenitor compartment Scand J Haematol 1984;33:27-34
4. Smeland E, Funderud S, Ruud E, et al. Characterization of two murine monoclonal antibodies reactive with human B cells. Scand J Immunol 1985;21:205-214
5. Ugelstad J, Rembaum A, Kemshead, J T. et al. Preparation and biomedical application of monodispersed polymer particles. In: David SS, Illum L, McVie JC, et al, eds. Microspheres and drug therapy: pharmaceutical and medical aspects. Amsterdam: F Science Publishers BV, 1984:365-382
6. Moir Dj, Ghosh Ak, Abdulaztz Z, et al. Immunoenzymatic staining of haematological samples with monoclonal antibodies. Br J Haematol 1983;55:395-410
7. Dinsmore Re, Reich Lm, Kapoor N, et al. ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation. Br J Haematol 1983;54:441-449
8. Kvalheim G, Sørensen O, Fodstad Ø, et al. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 1988;3:31-41
9. Janossy G. Bone marrow purging. Immunol Today 1987;8:253-255
10. Pesando Jm, Graf L. Differential expression of HLA-DR, -DQ, and -DP antigens on malignant B cells. J Immunol 1986;136:4311- 4318
11. Szer J, Deeg Hj, Appelbaum Fr, et aL Failure of autologus marrow rcconstitution after cytolytic treatment of marrow with anti-la monoclonal antibody. Blood 1985;65:819- 822
12. Berenson Rj, Bensinger wl Kalamasz D, et al. Engraftment of dogs with la-positive marrow cells isolated by avidin-biotin immunoadsorption. Blood 1987;69:1363-1367
13. Tiercy J-M, Gorski J, Jeannet M, et al. Identification and distribution of three serologically undetected alleles of HLA-DR by oligonucleotide. DNA typing analysis. Proc Natl Acad Sci USA 1988;85:198-202
14. Irle C, Jaques D, Tiercy J-M, et al. Functional polymorphism of each of the two HLA-DR β-chain loci demonstrated with antigen-specific DR3- and DRw52-restricted T-cell clones. J Exp Med 1988;167:853-872
15. Maraninchi D, Mannoni P, Mascret B, et al. In vitro marrow purging with anti-DR monoclonal antibodies and complement in high risk ALL and lymphomas. Presented at the 12th annual meeting of the European Cooperative Group for Bone Marrow Transplantation, 1986